VANCOUVER, British Columbia, Sept. 7, 2010 (GLOBE NEWSWIRE) -- biOasis Technologies Inc. (TSX-V:BTI) is pleased to announce that preclinical data on its proprietary Transcend™ (p97) technology for delivery of drugs into the brain was presented during the 13th International Symposium of the Blood-Brain Barrier, held in Zurich, Switzerland from Sept. 2 - 4, 2010.
